Quantitative and Qualitative Assessment of Urinary Activity of 18F-Flotufolastat-PET/CT in Patients with Prostate Cancer: a Post Hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies
Conclusions18F-Flotufolastat urinary activity did not influence disease assessment for the majority of patients. While this study was not designed as a head-to-head comparison, the median bladder SUVs are lower than previously reported values for other renally cleared PSMA-PET radiopharmaceuticals.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
More News: Biology | Bladder Cancer | Cancer | Cancer & Oncology | Molecular Biology | Nuclear Medicine | PET Scan | Prostate Cancer | Renal Failure | Study